Figure S3


A
Percentage of gene
p=0.05 reference
p-value
Co-expressed genes from UALCAN up in poor prognosis
- Log10 (p-value)
Biological pathway
Mitotic Prometaphase
Formation and Maturation of mRNA Transcript
Gene Expression
Mitotic M-M/G1 phases
DNA Replication
Cell Cycle, Mitotic
6,6%
9,5%
15,6%
13%
14%
16,3%
p < 0.001
Percentage of genes
Co-expressed genes from bcGeneXMiner up in poor prognosis
Cell Cycle Checkpoints
Mitotic Prometaphase
M Phase
Mitotic M-M/G1 phases
DNA Replication
Cell Cycle, Mitotic
11,2%
11,2%
14,9%
22,1%
23,7%
28,1%
B
Co-expressed genes from UALCAN up in good prognosis
ErbB receptor signaling network
Syndecan-1-mediated signaling events
Signaling events mediated by VEGFR1 and VEGFR2
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
Thrombin/protease-activated receptor (PAR) pathway
PAR1-mediated thrombin signaling events
29,1%
28,9%
Co-expressed genes from bcGeneXMiner up in good prognosis
NOSTRIN mediated eNOS trafficking
Smooth Muscle Contraction
anandamide degradation
FOXA1 transcription factor network
Mesenchymal-to-epithelial transition
Epithelial-to-mesenchymal transition
1,6%
3,3%
4,9%
13,1%
14,8%
p = 1
p = 0,622
p = 0,303
p = 0,009